Prospect: information for the user
CEVENFACTA 1 mg (45 kIU), powder and solvent for injectable solution
CEVENFACTA 2 mg (90 kIU), powder and solvent for injectable solution
CEVENFACTA 5 mg (225 kIU), powder and solvent for injectable solution
eptacog beta (activated)
This medicine is subject to additional monitoring, which will expedite the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this prospect carefully before starting to use this medicine, because it contains important information for you.
CEVENFACTA contains the active ingredient eptacog beta (activated), a recombinant human coagulation factor VIIa (FVIIarh).
CEVENFACTA is used in adults and adolescents (12 years of age or older) who were born with hemophilia A or B and who have developed inhibitors (antibodies). It is used for:
- the treatment of bleeding episodes,
- the management of bleeding during surgery.
How CEVENFACTA works
This medication acts by forming a blood clot at the site of bleeding, when the body's own coagulation factors do not function.
Do not use CEVENFACTA
- if you are allergic to eptacog beta (activated) or any of the other components of this medication (listed in section 6).
- if you are allergic to rabbits or rabbit proteins.
Warnings and precautions
Before starting your treatment with CEVENFACTA, inform your doctor:
Patients with known casein allergy may have a higher risk of hypersensitivity reactions. If signs or symptoms of hypersensitivity appear, discontinue treatment and seek immediate medical attention. Symptoms may include urticaria (skin swelling with pruritus), itching, hives, difficulty breathing, swelling around the mouth and throat, chest oppression, wheezing, dizziness or fainting, and decreased blood pressure.
Although not observed, the following reactions may occur during CEVENFACTA treatment:
If you experience any of these reactions, consult your doctor before continuing to use CEVENFACTA.
It is essential to record the batch number of your CEVENFACTA. Each time you use a new CEVENFACTA container, note the date and batch number (listed on the container, after «Lot») and store that information in a safe place.
Adolescents
The warnings and precautions indicated apply to both adults and adolescents (12 years of age or older).
Other medications and CEVENFACTA
Inform your doctor if you have taken recently or may need to take any other medication.
You must consult your doctor before using CEVENFACTA if
since the combination of these medications with CEVENFACTA may increase the risk of thromboembolic events (blood clots in veins).
You must consult your doctor before starting to use CEVENFACTA with these medications.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor before using this medication.
Driving and operating machinery
Dizziness may occur after administration of CEVENFACTA. You must avoid driving or operating machinery while experiencing this symptom.
CEVENFACTA contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per injection, that is essentially «sodium-free».
The use of this medication should be initiated and supervised by a doctor with experience in the treatment of hemophilia and/or bleeding disorders.
CEVENFACTA comes in powder form and must be prepared (reconstituted) with a solvent and injected into a vein (intravenous injection). Consult the usage guide instructions found at the end of this prospectus (section 7).
Self-administration
Medication injection requires special training. Do not attempt self-administration unless your doctor or hemophilia treatment center has taught you how to do it.
Many people with inhibitors learn to self-inject themselves or with the help of a family member. Once informed, you will need an additional injection equipment, apart from your CEVENFACTA kit, to properly treat your bleeding episodes at home. Make sure you have all the necessary injection equipment before preparing the medication for injection. This additional injection equipment will be provided by your healthcare professional (e.g., your pharmacist or hemophilia treatment center).
CEVENFACTA can be injected at a hemophilia treatment center, at your doctor's office, or at home. It is essential to treat the first sign of bleeding to control it.
Start the bleeding treatment as soon as possible, ideally within 2 hours.
?In the case of mild or moderate bleeding (e.g., joint, superficial muscle, soft tissue, and mucous membranes), treat yourself as soon as possible, ideally at home.
?In the case of severe bleeding (e.g., limb hemorrhage or life-threatening, intracranial hemorrhage or gastrointestinal hemorrhage), contact your doctor.
Generally, severe bleeding is treated in the hospital, but the first dose of CEVENFACTA can be administered on the way to the healthcare facility.
Do not treat yourself for more than 24 hours without consulting your doctor.
?Each time you use this medication, inform your healthcare professional as soon as possible.
?If bleeding is not controlled within 24 hours, contact your healthcare professional or emergency services immediately. Generally, you will need hospital assistance.
To reconstitute the medication before administration, follow the guidelines in theUsage Instructionsfound at the end of this prospectus (section 7).
Inject the solution into the vein for 2 minutes or less.
Follow exactly the administration instructions for this medication indicated by your doctor. In case of doubt, consult your doctor again.
Dose
Your healthcare professional will indicate the amount of CEVENFACTA to use and when to administer the medication based on your weight, condition, and type of bleeding.
Bleeding episode treatment
The treatment with this medication should be started as soon as the bleeding episode occurs.
Mild and moderate bleeding:
Home treatment should not last more than 24 hours in the case of mild to moderate bleeding episodes. Continuing home treatment after 24 hours should only be considered after a consultation at a hemophilia treatment center.
Severe bleeding:
Seek immediate medical attention if you experience signs or symptoms of severe bleeding at home.
To avoid any delay in treatment, the first dose can be administered on the way to the hemophilia treatment center or to your doctor's office.
Follow exactly the administration instructions for the medication contained in this prospectus or indicated by your doctor. In case of doubt, consult your doctor again.
Administration form
To reconstitute the medication before administration and administration instructions, follow the guidelines in theUsage Instructionsfound at the end of this prospectus (section 7).
If you use more CEVENFACTA than you should
If you use too much CEVENFACTA, go to the doctor immediately.
If you forgot to use CEVENFACTA:
If you forgot to use CEVENFACTA, consult your doctor.
If you have any other questions about using this medication, ask your doctor.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Frequent Adverse Effects
(may affect up to 1 in 10 people)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the national notification system included in theAppendix V. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and on the box after EXP. The expiration date is the last day of the month indicated.
Store below 30 °C.
Do not freeze.
Store the vial in the outer packaging to protect it from light.
To reconstitute CEVENFACTA, use exclusively the material provided in the kit.
After reconstitution, the product must be stored in the vial and administered within a period of 4 hours. Any remaining solution must be discarded 4 hours after reconstitution.
Do not use this medication if you observe that the liquid contains particles or is cloudy after mixing.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of medications that you no longer need. In this way, you will help protect the environment.
Composition of CEVENFACTA
Powder:arginine hydrochloride, isoleucine, sodium citrate dihydrate, glycine, lysine hydrochloride, polisorbate 80, hydrochloric acid (for pH adjustment).
Solvent:water for injection preparations.
See section 2 «CEVENFACTA contains sodium»
The powder for injectable solution contains: 1 mg/vial (which corresponds to 45 kIU/vial), 2 mg/vial (which corresponds to 90 kIU/vial), 5 mg/vial (which corresponds to 225 kIU/vial).
After reconstitution, the concentration of the solution is approximately 1 mg/ml (45 kIU/ml) of eptacog beta (activated). 1 kIU is equal to 1,000 IU (International Units).
Appearance of CEVENFACTA and contents of the package
The vial of powder contains lyophilized powder of white to off-white and the pre-loaded syringe contains a transparent and colorless solution. The reconstituted solution must be transparent to slightly opaque.
Each package of CEVENFACTA contains:
Presentations: 1 mg (45 kIU), 2 mg (90 kIU) and 5 mg (225 kIU).
Marketing Authorization Holder
Laboratoire français du Fractionnement et des Biotechnologies
Tour W
102 Terrasse Boieldieu, 19ème Étage
92800 Puteaux
France
Manufacturer
LFB Biotechnologies
Zone d’activité de Courtab?uf
3 Avenue des Tropiques
91940 Les Ulis
France
+33 1 69 82 70 10
For more information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
Last update of this leaflet:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
This leaflet is available in all languages of the European Union/European Economic Area on the website of the European Medicines Agency.
INSTRUCTIONS FOR USE
READ THIS LEAFLET CAREFULLY BEFORE STARTING TO USE CEVENFACTA
CEVENFACTA comes in powder form. Before injection, it must be prepared (reconstituted) with the solvent provided in the syringe. The solvent is water for injection preparations. The reconstituted CEVENFACTA must be injected into a vein (only for intravenous use).
This kit provides the necessary equipment to reconstitute the medication. Additional materials are needed to inject the medication after reconstitution. These materials will be provided by your healthcare professional (e.g., your pharmacist or your hemophilia treatment center).
Your doctor or nurse will show you and/or your caregiver how to prepare and inject CEVENFACTA. Do not use this kit without proper training from your healthcare professional or hemophilia treatment center.
Use a clean and germ-free (aseptic) technique when preparing and injecting the medication.
This CEVENFACTA kit contains:
You will also need a sterile injection set (needle and butterfly), a plastic syringe, alcohol-impregnated sterile gauze, and a puncture-proof container that meets local regulations and guidelines.These materials are not included in the CEVENFACTA package.These materials will be provided by your healthcare professional (e.g., your pharmacist or your hemophilia treatment center).
1) Gather the equipment and prepare the vial
Do not use the kit if the safety seal is broken or if there are signs of contamination.Use a new one instead.
Do not use it after the expiration date.
Do not use the contents if it has fallen or is damaged.Use a new kit instead.
Do not use the vial and syringe pre-loaded heated in any other way.
If the plastic cap is loose or the vial comes without a cap, do not use it.
2) Place the vial adapter
If the paper protector is not completely sealed or is broken, do not use the adapter.
Do not remove the vial adapter from its protective packaging with your fingers.If you touch the spike of the adapter with your fingers, you may transmit germs.
Once you have removed the plastic cover, do not touch the top of the adapter to avoid transmitting germs.
NOTE:The 5 mg vial adapter may not be flat in contact with the vial, but it is still fully functional. As mentioned earlier, your CEVENFACTA kit contains a single vial adapter (the one suitable for the vial included in the kit).
3) Place the pre-loaded syringe and introduce the plunger rod
Avoid touching the needle tip to prevent transmitting germs from your fingers.
If the syringe cap is loose or the syringe came without it, do not use it.
Be careful not to tighten it too much, as you will need to remove the syringe later.
4) Mix the medication in the vial
Do not push too quickly, as this may form excessive foam and air in the vial.
Do not shake the vial, as this may form foam and air.
Do not use the product if the solution contains any particles or is turbid after mixing.Repeat the process with a new kit.
5) Remove the empty syringe from the vial adapter
Do not remove the vial adapter.
Do not touch the top of the vial adapter with the Luer-Lock stopper. If you touch it, you may transmit germs from your fingers.
6) Mix the vial (or vials) extra(s) and inject the dose
Do not use it if more than 4 hours have passed since reconstitution.
7) Dispose of the empty medication vials
Do not dispose of household waste.
Do not separate the vial from the vial adapter before disposing of them.
Do not re-use any of the elements contained in the kit.
Follow local regulations and guidelines for the proper disposal of the puncture-proof container.
Storage
CEVENFACTA comes in a kit that must be stored below 30 °C.
Do not open the contents of the kit until you are ready to use them.
Do not freeze or store in syringes containing the reconstituted CEVENFACTA solution.
Avoid exposing the reconstituted CEVENFACTA solution to direct light.
Important information
CEVENFACTA is only injected into a vein (intravenous administration). Do not inject it by any other route, such as under the skin (subcutaneous) or into a muscle (intramuscular). Contact your doctor, nurse, or pharmacist if you have any problems.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.